Max Planck Institute Study Reveals Why BET Inhibitors Fail in Cancer Treatment
A recent study conducted by the Max Planck Institute of Immunobiology and Epigenetics has provided insights into the failure of BET inhibitors in cancer treatment. BET inhibitors, designed to block BET proteins that activate oncogenes, have shown limited success in clinical trials despite promising laboratory results. The study highlights the distinct roles of two BET proteins, BRD2 and BRD4, in gene activation. BRD4 is involved in releasing RNA Polymerase II for active transcription, while BRD2 initiates transcription by organizing molecular machinery. Current inhibitors block both proteins simultaneously, leading to unpredictable effects. The study suggests that targeting these proteins separately could lead to more effective therapies. 
